Elizabeth M. Muhowski

The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation

Sean D. Reiff, Rose Mantel, Lisa L. Smith et al. · Cancer Discovery · 2018 · 161 citations · Full text

Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL

Sean D. Reiff, Elizabeth M. Muhowski, Daphne Guinn et al. · Blood · 2018 · 60 citations · Full text

First-in-Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non–Hodgkin Lymphoma

Jennifer A. Woyach, Deborah M. Stephens, Ian W. Flinn et al. · Cancer Discovery · 2023 · 45 citations

Targeting phosphatidylinositol 3 kinase-β and -δ for Bruton tyrosine kinase resistance in diffuse large B-cell lymphoma

Neeraj Jain, Satishkumar Singh, Amber Hart et al. · Blood Advances · 2020 · 30 citations · Full text

Intentional Modulation of Ibrutinib Pharmacokinetics through CYP3A Inhibition

Eric D. Eisenmann, Qiang Fu, Elizabeth M. Muhowski et al. · Cancer Research Communications · 2021 · 17 citations · Full text

Tumor Biology, Oral Bioavailability, Low Oral Bioavailability +11